Baxter to buy Gambro for $2.8 billion to boost dialysis
Baxter International, the U.S. maker of blood products and intravenous drugs, agreed to buy Swedish kidney-dialysis competitor Gambro AB for $2.8 billion to expand its dialysis-equipment business.
This premium content is reserved for Daily Business Review subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now